189 related articles for article (PubMed ID: 31332252)
1. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.
Jureczek J; Bergmann R; Berndt N; Koristka S; Kegler A; Puentes-Cala E; Soto JA; Arndt C; Bachmann M; Feldmann A
Sci Rep; 2019 Jul; 9(1):10547. PubMed ID: 31332252
[TBL] [Abstract][Full Text] [Related]
2. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
4. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Máthé D; Hegedüs N; Szigeti K; Videira PA; Bachmann M; Arndt C
J Exp Clin Cancer Res; 2020 May; 39(1):77. PubMed ID: 32370811
[TBL] [Abstract][Full Text] [Related]
5. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
7. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
[TBL] [Abstract][Full Text] [Related]
8. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
Albert S; Arndt C; Feldmann A; Bergmann R; Bachmann D; Koristka S; Ludwig F; Ziller-Walter P; Kegler A; Gärtner S; Schmitz M; Ehninger A; Cartellieri M; Ehninger G; Pietzsch HJ; Pietzsch J; Steinbach J; Bachmann M
Oncoimmunology; 2017; 6(4):e1287246. PubMed ID: 28507794
[TBL] [Abstract][Full Text] [Related]
9. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
10. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
[TBL] [Abstract][Full Text] [Related]
11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
12. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS
Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995
[TBL] [Abstract][Full Text] [Related]
13. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.
Mitwasi N; Feldmann A; Bergmann R; Berndt N; Arndt C; Koristka S; Kegler A; Jureczek J; Hoffmann A; Ehninger A; Cartellieri M; Albert S; Rossig C; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 Dec; 8(65):108584-108603. PubMed ID: 29312553
[TBL] [Abstract][Full Text] [Related]
14. Retargeting of UniCAR T cells with an
Bachmann D; Aliperta R; Bergmann R; Feldmann A; Koristka S; Arndt C; Loff S; Welzel P; Albert S; Kegler A; Ehninger A; Cartellieri M; Ehninger G; Bornhäuser M; von Bonin M; Werner C; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2018 Jan; 9(7):7487-7500. PubMed ID: 29484126
[TBL] [Abstract][Full Text] [Related]
15. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
[TBL] [Abstract][Full Text] [Related]
16. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Arndt C; Feldmann A; Koristka S; Schäfer M; Bergmann R; Mitwasi N; Berndt N; Bachmann D; Kegler A; Schmitz M; Puentes-Cala E; Soto JA; Ehninger G; Pietzsch J; Liolios C; Wunderlich G; Kotzerke J; Kopka K; Bachmann M
Oncoimmunology; 2019; 8(11):1659095. PubMed ID: 31646084
[TBL] [Abstract][Full Text] [Related]
17. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
Bachmann M
Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431
[TBL] [Abstract][Full Text] [Related]
18. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Peschke JC; Bergmann R; Mehnert M; Gonzalez Soto KE; Loureiro LR; Mitwasi N; Kegler A; Altmann H; Wobus M; Máthé D; Szigeti K; Feldmann A; Bornhäuser M; Bachmann M; Fasslrinner F; Arndt C
Br J Haematol; 2023 Sep; 202(6):1137-1150. PubMed ID: 37460273
[TBL] [Abstract][Full Text] [Related]
19. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Arndt C; Pietzsch J; Novo C; Videira P; Bachmann M
Blood Cancer J; 2018 Aug; 8(9):81. PubMed ID: 30190468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
